Early Patient Stratification is Critical to Enable Effective and Personalised Drug Discovery and Development By Dr David A Fryburg, Dr Diane H Song and Dr David de Graaf With the current chances of an efficacious outcome in Phase II for novel mechanisms being in the region of 1 in 5,… Read More
Next Generation Flow Chemistry and Biology Platforms: The Impact on Small Molecule Drug Discovery By Dr J Mark Treherne, Dr David M Parry and Christopher N Selway Can the next generation of flow chemistry and biology platforms be fully integrated to transform the efficiency of small-molecule drug discovery for pharmaceutical… Read More
Assessing the Value of R&D Partnerships By Dr David A Pardoe, Dr Jackie Hunter MBE, Dr Robert M Cooke and Dr Paul Barrett In response to the need to increase the return on investment in R&D, many large Pharma companies are shifting from an internal fixed resource model to more… Read More
Neutron Scattering Provides Unique Insights for Drug R&D By Dr Martyn Bull Drug discovery and development is a long and expensive process. Techniques, such as computer modelling, that make the search for promising candidates easier are usually taken up enthusiastically. Neutron scattering, an emerging technique in this field, can provide… Read More
Overcoming Bottlenecks in Drug Discovery By Dr Trevor Perrior Developing a new drug is an expensive and time-consuming process. The best current estimate puts the cost of developing a single new drug at close to $1 billion. After a drug candidate has entered the clinical trial process it takes, on… Read More
Enterprise ELNs as a Foundation for Preclinical Drug Development By Simon Beaulah, Dr Paul Denny- Gouldson and Dr Scott Weiss To have real business impact within preclinical drug development, Enterprise ELNs (Electronic Laboratory Notebooks) must provide a secure, scalable and searchable data management backbone across all disciplines focused on development… Read More
Towards Unbiased Biomarker Discovery Dr Jens Hoefkens High-throughput molecular profiling technologies are routinely applied for biomarker discovery to make the drug discovery process more efficient and enable personalised medicine. The ability to find novel biomarkers rests on large-scale data generation and unbiased data analysis. Over the past decade, biomarker discovery… Read More
By William Downey, Cindy Liu and Dr Jennifer Hartigan A recent report examines the trends in utilisation of compound libraries, as well as the impact of profiling on the size of screening decks. The drivers for choosing between large or focused libraries may be different, but the ultimate goal remains… Read More
Utilising 3D nuclear DNA methylation patterns in cell-based assays for epigenetic drug screening By Professor Jian Tajbakhsh, Professor Arkadiusz Gertych and Professor Daniel L Farkas Since epigenetic changes are thought to underlie a wide range of complex diseases, the scope of epigenetic drug therapy is likely to expand, as epigenetic… Read More
Free Online Resources Enabling Crowd-Sourced Drug Discovery By Dr Antony J. Williams, Valery Tkachenko, Dr Chris Lipinski, Professor Alexander Tropsha and Dr Sean Ekins The availability of freely accessible online resources to enable and support drug discovery has blossomed in recent years. The PubChem platform is now accompanied by a… Read More
Integrating Computational Methods and Drug Discovery - Avoiding pitfalls in chemical space By Alexandre Ismail and Professor Philippe Manivet The immensity of the task in discovering suitable molecules for development among the vast number which are theoretically available is well stated. With 90% of potentially efficacious compounds failing at latter… Read More
Structure-Based Drug Design - Will crystallisation 'chaperones' make all proteins crystallisable? By Dr Chun-wa Chung Macromolecular x-ray crystallography is usually an integral part of small molecule drug discovery for soluble targets. Recent advances in the crystallography of membrane proteins, such as ion channels and G-protein-coupled receptors, have opened up the… Read More
Share Share Tweet Email A perspective on scientific innovation in the pharmaceutical industry A perspective on scientific innovation in the pharmaceutical industry By Dr Joseph B. Bolen With a tarnished reputation and a lack of sustainable innovation this article argues that, maybe, it is time for the pharmaceutical industry to… Read More
Overcoming the Limitations of Chemical Structure By Dr Andy Vinter, Dr Steve Gardner and Dr Sally Rose The pharmaceutical business has been profoundly hampered by a ubiquitous and unexpected obstacles; the way it draws its chemical compounds. Scientists, patent agents and business decision makers from R&D, safety, and in-licensing are… Read More
The Benefits of Biological Modelling By Gordon Webster The enormous challenge posed by the complexity of biological systems represents a potential intellectual impasse to researchers and threatens to stall future progress in basic biology and healthcare. In recent years, increasing reliance on correlative approaches to biology has failed to resolve… Read More
Generation II DNA Sequencing Technologies By Dr Stephen F. Kingsmore, Dr Jenny C. van Velkinburgh, Dr Joann Mudge, and Dr Gregory D. May Generation II DNA sequencing has been widely heralded as a disruptive technology, generating tens of millions of random short sequences at efficiencies up to 20,000-fold greater than… Read More